DUBLIN, November 8, 2017 /PRNewswire/ --

The "CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023" report has been added to Research and Markets' offering.

CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023

report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market.

CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered.

Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.

CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023 report highlights:

• Market Opportunity Assessment: More than US$ 60 Billion by 2023
• Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
• Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
• Dosage & Price Analysis on Key Drugs
• Mechanism of CD Antigen Cancer Therapeutics
• Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
• Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

Key Topics Covered:

1. Introduction to CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics

6. Major CD Antigens as Targets for Cancer Therapy

7. Major CD Antigens as Cancer Diagnostic Agents

8. Major CD Antigens in Cancer Research

9. Global CD Antigen Based Therapeutics Market Overview

10. Price & Dosage Analysis of Major CD Antigen Based Cancer Therapies

11. Marketed Cancer CD Antigen Inhibitors Clinical & Patent Insight

12. Global CD Antigen Cancer Therapy Market Dynamics

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

• Cancer CD3 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD4 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD7 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD19 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD20 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD22 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD 26 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD27 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD30 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD33 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD38 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD44 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD45 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD46 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD 47 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD52 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD55 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD56 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD66 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD70 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD71 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD98 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD200 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD223 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD248 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD274 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
• Cancer CD319 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase

Companies Featured

• AryoGen Biopharma
• Biocad
• Biogen Idec
• Celltrion
• Genentech
• Genmab
• GLYCART Biotechnology
• Hetero Drugs
• mAbxience
• MedImmune
• Merck
• Sandoz
• UCB
  

For more information about this report visit https://www.researchandmarkets.com/research/922ksw/cd_antigen_cancer

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets